Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy
NCT06858319Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of zigakibart in immunoglobulin A nephropathy (IgAN), sponsored by Novartis. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
zigakibart
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06858319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858319.